Peptimmune has received a US patent which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.
Peptimmune's PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis.
1st August 2008
By Staff Writer for Pharmaceutical-Review
Peptimmune has received a US patent which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.
Peptimmune's PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis.
» Read More
===========================================
If you want to leave a comment to this article, you need to return-to
(or remain on) - this page
============================================